SGPL1 and rhabdomyosarcoma: So far, only a few studies are available for SGPL1 expression and sphingolipid-metabolism in correlation with tumor progression and treatment success in pediatric rhabdomyosarcoma (RMS), which is the most frequent soft tissue sarcoma.